PD-L1 Biomarker Testing Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 220

To learn more about this report, request a free sample copy

PD-L1 Biomarker Testing Market Overview

The report is titled as ‘PD-L1 Biomarker Testing Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the PD-L1 Biomarker Testing market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. PD-L1 Biomarker Testing market is expected to grow with significant rate in the near future.

In 2021, the U.S. PD-L1 biomarker testing market was accounted for more than US$ 294 Mn

PD-L1 Biomarker Testing Introduction

Biomarker can be understood as a molecule of a human body - acquired from body fluids, blood, or tissues - that can be investigated to examine the health of the person. Examining an individual for the existence of diseases via biomarkers and evaluating molecular signs of health is known as biomarker testing. On the same note, PD-L1 can be perceived as a protein whose existence signifies a tumor, surfaced as an early biomarker to be checked in immunotherapy clinical trials. To put it differently, PD-L1 is a protein that holds the role of a “brake” to maintain the body's immune responses under restraint.

PD-L1 is likely to be found on some normal cells and in higher-than-normal quantities on some kinds of cancer cells. The PD-L1 test measures the amount of PD-L1 protein on cancer cells. If an individual’s cancer cells are composed of a higher amount of PDL1, one is likely to benefit from a treatment known as immunotherapy. Immunotherapy is basically a therapy that accelerates an individual’s immune system to assist it in recognizing and fighting against cancer cells.

Moreover, immunotherapy has been proven to be highly effective in treating various kinds of cancers. It also tends to have lesser adverse effects than other cancer therapies. One of the primary factors that is majorly projected to drive the growth of the global PD-L1 biomarker testing market is the high prevalence of cancer all around the world.

Rapid technological advances in cancer screening procedures is expected to drive the growth of PD-L1 Biomarker Testing Market

Cancer has turned out to be the leading cause of deaths among the population all around the world. There were an estimated 18.1 million cancer cases around the world in the year 2020, which is disastrous and makes one shudder with fear. With this growing global burden, prevention of cancer is one of the most significant public health challenges of the 21st century. Having said that, there have been numerous cancer screening processes which help in early diagnosis and efficient treatment of the disease.

Moreover, what once appeared impractical and absurd in cancer research is now a reality by virtue of a number of technological advances and innovations that have paved its way to major breakthroughs in the ways we determine, visualize, comprehend, and treat cancer. In the same manner, PDL1 test is an approach that measures the amount of PDL1 on cancer cells. PDL1 is a protein that assists in keeping immune cells from attacking non-harmful cells in the body. If an individual’s cancer cells have a huge amount of PDL1, one may aid from a treatment known as immunotherapy. Immunotherapy can be understood as the therapy that accelerates one’s immune system to help it detect and combat cancer cells. Immunotherapy has been proven to be highly efficient in treating various kinds of cancers.

As medical professionals and researchers explore more about the systems and mechanisms of cancer, more and more new diagnostic tools are being developed as well as the existing diagnostic approaches are being further polished and refined. Likewise, PD-L1 biomarker testing is also witnessing several innovative upgrades and advancements in its technology. For instance, Agilent Technologies, Inc., an American analytical instrumentation development and manufacturing company, revealed it has obtained CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to direct alternatives for the first-line treatment of adult patients suffering from HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.

Notably, gastric (stomach) cancer is one of the fifth most common cancers and the fourth major cause of cancer death all across the world, with around 1,000,000 new cases and about 770,000 casualties in 2020. Likewise, Esophageal cancer is the seventh most common cancer and the sixth major cause of death from cancer around the globe, with nearly 600,000 new cases and about 540,000 deaths in 2020. Simultaneously with cancers of the gastroesophageal junction, they form an significant – and developing – worldwide health concern.

PD-L1 Biomarker Testing Market Segmentation

The global PD-L1 Biomarker Testing market is segmented on the basis of type, indication, end user, and region.

By Type

22C3 Assay Kit

28-8 Assay Kit

SP142 Assay Kit

SP263 Assay Kit

By Indication

Non-small Cell Lung Cancer (NSCLC)

Melanoma

Renal Cell Carcinoma

Gastrointestinal Tract Malignancies

Ovarian Cancer

Hematological Malignancies

By End-User

Hospitals

Diagnostic Laboratories

Specialty Clinics

By Region

North America

Latin America

Asia Pacific

Europe

Middle East

Africa

PD-L1 Biomarker Testing Market Key Players

Some of the key participating players in global PD-L1 Biomarker Testing market are:

Agilent Technologies, Inc.

NeoGenomics Laboratories

F. Hoffmann-La Roche Ltd

HalioDx

Abcam plc

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

New product designs and launches

Current product compliance

Reimbursement

Concerns for use of PD-L1 Biomarker Testing

Advantages of PD-L1 Biomarker Testing

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the market.


PD-L1 Biomarker Testing Market

To learn more about this report, request a free sample copy


Select License Type

Frequently Asked Questions

In 2021, the U.S. PD-L1 biomarker testing market was accounted for more than US$ 294 Mn

High prevalence of cancer worldwide, rapid technological advances in cancer screening procedures, and rise in number of initiatives and support programmes to combat cancer

The global PD-L1 biomarker testing market is segmented on the basis of type, indication, end user, and region

Agilent Technologies, Inc.. NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd., HalioDx, Oxford BioDynamics, and Abcam plc.


This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK